Get the Stockscreener App
32.77
1.52%
0.49
After Hours:
32.77
Atricure Inc stock is traded at $32.77, with a volume of 337.65K.
It is up +1.52% in the last 24 hours and down -5.21% over the past month.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
See More
Previous Close:
$32.28
Open:
$32.46
24h Volume:
337.65K
Relative Volume:
0.58
Market Cap:
$1.65B
Revenue:
$447.57M
Net Income/Loss:
$-38.92M
P/E Ratio:
-39.48
EPS:
-0.83
Net Cash Flow:
$-1.15M
1W Performance:
+2.73%
1M Performance:
-5.21%
6M Performance:
+7.23%
1Y Performance:
+43.92%
1-Day Range:
$32.12
$32.85
1-Week Range:
$31.00
$33.00
52-Week Range:
$20.20
$43.11
Atricure Inc Stock (ATRC) Company Profile
Name
Atricure Inc
Sector
Industry
Phone
513-755-4100
Address
7555 INNOVATION WAY, MASON, OH
Compare ATRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
32.77 | 1.65B | 447.57M | -38.92M | -1.15M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
543.41 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
172.25 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
88.28 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
258.00 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
218.80 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Resumed | JP Morgan | Overweight |
| Apr-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-29-23 | Initiated | UBS | Buy |
| Aug-05-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-18-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Reiterated | Needham | Buy |
| Apr-07-20 | Initiated | Oppenheimer | Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jan-24-20 | Reiterated | Needham | Buy |
| Aug-13-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Apr-12-19 | Initiated | JP Morgan | Overweight |
| Oct-04-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Needham | Buy |
| Aug-02-18 | Reiterated | Stifel | Buy |
| Jun-18-18 | Reiterated | Needham | Buy |
| Apr-27-18 | Reiterated | Needham | Buy |
| Jan-16-18 | Reiterated | Needham | Buy |
| Nov-02-17 | Reiterated | Needham | Buy |
| Jul-28-17 | Reiterated | Needham | Buy |
| May-30-17 | Resumed | Piper Jaffray | Overweight |
| Jun-30-16 | Resumed | JMP Securities | Mkt Outperform |
| Oct-28-15 | Reiterated | Needham | Buy |
| Oct-06-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-06-15 | Reiterated | Needham | Buy |
View All
Atricure Inc Stock (ATRC) Latest News
Cryoablation Probe Market Size, Share | Industry Report 2030 - Grand View Research
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year? - Yahoo Finance
Transcript : AtriCure, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - MarketScreener
AtriCure at Goldman Sachs Conference: Strategic Growth Insights - Investing.com India
AtriCure at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com UK
Ameriprise Financial Inc. Invests $295,000 in AtriCure, Inc. (NASDAQ:ATRC) - Defense World
Global Cardiac Ablation Market: Advancements in Minimally Invasive Procedures and 13% CAGR by 2030 - PharmiWeb.com
AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Jane Street Group LLC - Defense World
AtriCure (NASDAQ:ATRC) Downgraded to “Hold” Rating by Wall Street Zen - Defense World
(ATRC) Investment Analysis - news.stocktradersdaily.com
AtriCure’s chief scientific officer sells $83,600 in stock By Investing.com - Investing.com India
Insider Sell: Vinayak Doraiswamy Sells 2,500 Shares of AtriCure Inc (ATRC) - GuruFocus
AtriCure’s chief scientific officer sells $83,600 in stock - Investing.com Australia
Investors push AtriCure (NASDAQ:ATRC) 3.9% lower this week, company's increasing losses might be to blame - simplywall.st
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $823,000 Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC) - Defense World
AtriCure, Inc. (ATRC) Stock Analysis: Evaluating a 52.52% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Deutsche Bank AG - Defense World
AtriCure (NASDAQ:ATRC) Upgraded by Wall Street Zen to “Buy” Rating - Defense World
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference | ATRC Stock News - GuruFocus
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Yahoo Finance
Bank of America Corp DE Sells 208,694 Shares of AtriCure, Inc. (NASDAQ:ATRC) - Defense World
AtriCure Inc (ATRC) Trading 3.4% Higher on May 20 - GuruFocus
Focus Partners Wealth Acquires Shares of 16,306 AtriCure, Inc. (NASDAQ:ATRC) - Defense World
D. E. Shaw & Co. Inc. Sells 49,834 Shares of AtriCure, Inc. (NASDAQ:ATRC) - Defense World
(ATRC) On The My Stocks Page - news.stocktradersdaily.com
AtriCure Stockholders Approve Stock Incentive Plan Amendment - TipRanks
Left Atrial Appendage Devices Market | Latest Trends, Growth, - openPR.com
AtriCure Names New COO, CFO - Medical Product Outsourcing
AtriCure Enrolls First Two Patients in DEEP Clinical Study - Medical Product Outsourcing
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect? - Yahoo Finance
Questex’s Fierce Healthcare Announces 2025 Fierce DEI Award Finalists - GlobeNewswire Inc.
When (ATRC) Moves Investors should Listen - news.stocktradersdaily.com
AtriCure Q1 2025 presentation: Revenue up 13.6%, raises full-year guidance - Investing.com
Dimensional Fund Advisors LP Purchases 136,015 Shares of AtriCure, Inc. (NASDAQ:ATRC) - Defense World
AtriCure CEO details growth trajectory toward becoming a $1B company - The Business Journals
AtriCure targets $517M-$527M revenue in 2025 with strong growth in appendage management and pain management - MSN
Left Atrial Appendage Closure Market to Set Phenomenal Growth - openPR.com
AtriCure, Inc. (NASDAQ:ATRC) Q1 2025 Earnings Call Transcript - Insider Monkey
Shareholders in AtriCure (NASDAQ:ATRC) have lost 40%, as stock drops 11% this past week - Yahoo Finance
AtriCure, Inc. (NASDAQ:ATRC) Screens Well But There Might Be A Catch - simplywall.st
Needham cuts AtriCure stock target to $44, maintains buy rating By Investing.com - Investing.com Nigeria
AtriCure price target lowered to $52 from $58 at BTIG - TipRanks
AtriCure price target lowered to $51 from $52 at Canaccord - TipRanks
AtriCure’s Strong Q1: Revenue Growth and Challenges - TipRanks
Needham cuts AtriCure stock target to $44, maintains buy rating - Investing.com Australia
UBS Adjusts AtriCure (ATRC) Price Target Amid Core Business Stre - GuruFocus
AtriCure, Inc. SEC 10-Q Report - TradingView
UBS Adjusts Price Target on AtriCure to $58 From $60, Maintains Buy Rating - marketscreener.com
14 Analysts Assess AtriCure: What You Need To Know - Benzinga
AtriCure (ATRC) Target Price Revised Amid Mixed Sector Performan - GuruFocus
Atricure Inc Stock (ATRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):